NYSEAMERICAN:PTN Palatin Technologies (PTN) Stock Forecast, Price & News $2.25 -0.03 (-1.32%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$2.25▼$2.4050-Day Range$2.10▼$3.1052-Week Range$2.08▼$9.48Volume48,676 shsAverage Volume77,473 shsMarket Capitalization$25.09 millionP/E RatioN/ADividend YieldN/APrice Target$50.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Palatin Technologies MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,566.7% Upside$60.00 Price TargetShort InterestBearish3.27% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.71) to ($1.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.53 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPalatin Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $60.00, Palatin Technologies has a forecasted upside of 2,566.7% from its current price of $2.25.Amount of Analyst CoveragePalatin Technologies has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.27% of the float of Palatin Technologies has been sold short.Short Interest Ratio / Days to CoverPalatin Technologies has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Palatin Technologies has recently increased by 5.37%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPalatin Technologies does not currently pay a dividend.Dividend GrowthPalatin Technologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PTN. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 6 people have searched for PTN on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Palatin Technologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.70% of the stock of Palatin Technologies is held by insiders.Percentage Held by InstitutionsOnly 9.03% of the stock of Palatin Technologies is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Palatin Technologies are expected to grow in the coming year, from ($2.71) to ($1.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Palatin Technologies is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palatin Technologies is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalatin Technologies has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Palatin Technologies (NYSEAMERICAN:PTN) StockPalatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.Read More Receive PTN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palatin Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address PTN Stock News HeadlinesMay 30, 2023 | uk.finance.yahoo.comPTN - Palatin Technologies, Inc.May 30, 2023 | finance.yahoo.comPalatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte ConferenceJune 8, 2023 | Altimetry (Ad)Surprising "Twist" Hands Biden Landslide Re-election?This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.May 21, 2023 | americanbankingnews.comPalatin Technologies (NYSEAMERICAN:PTN) Downgraded to Sell at StockNews.comMay 19, 2023 | americanbankingnews.comPalatin Technologies (NYSEAMERICAN:PTN) Announces Earnings Results, Misses Estimates By $0.24 EPSMay 19, 2023 | americanbankingnews.comPalatin Technologies (NYSE:PTN) Now Covered by Analysts at StockNews.comMay 17, 2023 | finance.yahoo.comPalatin Technologies, Inc. (AMEX:PTN) Q3 2023 Earnings Call TranscriptMay 17, 2023 | finance.yahoo.comQ3 2023 Palatin Technologies Inc Earnings CallJune 8, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 16, 2023 | markets.businessinsider.comLadenburg Thalmann & Co. Sticks to Its Buy Rating for Palatin Technologies (PTN)May 16, 2023 | markets.businessinsider.comPalatin Technologies (PTN) Receives a Buy from H.C. WainwrightMay 16, 2023 | finance.yahoo.comPalatin Technologies, Inc. (PTN) Reports Q3 Loss, Tops Revenue EstimatesMay 16, 2023 | markets.businessinsider.comPalatin Technologies Inc. Q3 Loss NarrowsMay 16, 2023 | finance.yahoo.comPalatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate UpdateMay 11, 2023 | msn.comHC Wainwright & Co. Reiterates Palatin Technologies (PTN) Buy RecommendationMay 11, 2023 | finance.yahoo.comTELA Bio, Inc. (TELA) Reports Q1 Loss, Misses Revenue EstimatesMay 11, 2023 | finance.yahoo.comPalatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023May 9, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN) and DermTech (DMTK)May 9, 2023 | finance.yahoo.comPalatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual ConferenceMay 8, 2023 | finance.yahoo.comPalatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader WebinarMay 1, 2023 | finance.yahoo.comPalatin Technologies to Host Key Opinion Leader WebinarMay 1, 2023 | markets.businessinsider.comLadenburg Thalmann & Co. Keeps Their Buy Rating on Palatin Technologies (PTN)April 27, 2023 | finance.yahoo.comPalatin Presents Initial Dry Eye Disease Phase 3 Clinical Data at the Association of Research in Vision and Ophthalmology 2023 Annual ConferenceApril 25, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Palatin Technologies (PTN)April 25, 2023 | finance.yahoo.comPalatin Presents Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Regarding a Potential Treatment for GlaucomaApril 19, 2023 | finance.yahoo.comPalatin Announces Preliminary Third Quarter Fiscal 2023 Vyleesi® Product Revenue ResultsApril 19, 2023 | americanbankingnews.comCV Sciences (OTCMKTS:CVSI) & (NYSE:PTN) Financial ComparisonSee More Headlines PTN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTN Company Calendar Last Earnings5/16/2023Today6/08/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:PTN Previous SymbolNYSE:PTN CUSIPN/A CIK911216 Webwww.palatin.com Phone(609) 495-2200Fax609-495-2202Employees26Year FoundedN/APrice Target and Rating Average Stock Price Forecast$60.00 High Stock Price Forecast$70.00 Low Stock Price Forecast$50.00 Forecasted Upside/Downside+2,122.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,200,000.00 Net Margins-766.11% Pretax Margin-887.11% Return on Equity-278.73% Return on Assets-116.40% Debt Debt-to-Equity Ratio0.01 Current Ratio2.05 Quick Ratio1.99 Sales & Book Value Annual Sales$1.47 million Price / Sales17.07 Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book1.28Miscellaneous Outstanding Shares11,150,000Free Float10,294,000Market Cap$25.09 million OptionableNot Optionable Beta1.01 Key ExecutivesCarl SpanaPresident, Chief Executive Officer & DirectorStephen T. WillsCOO, CFO, Secretary, Treasurer & Executive VPMichael B. RaizmanChief Medical OfficerJohn DoddSenior Vice President-Preclinical DevelopmentJames E. HattersleySenior Vice President-Business DevelopmentKey CompetitorsAmarillo BiosciencesOTCMKTS:AMARCocrystal PharmaNASDAQ:COCPOnconova TherapeuticsNASDAQ:ONTXMetacrineNASDAQ:MTCRLipocineNASDAQ:LPCNView All CompetitorsInsiders & InstitutionsJane Street Group LLCBought 37,479 shares on 5/16/2023Ownership: 0.336%Susquehanna International Group LLPSold 43,398 shares on 5/16/2023Ownership: 0.173%CIBC Asset Management IncBought 15,004 shares on 5/12/2023Ownership: 0.135%Dimensional Fund Advisors LPSold 4,887 shares on 5/12/2023Ownership: 0.113%Montis Financial LLCBought 20,964 shares on 5/11/2023Ownership: 0.188%View All Insider TransactionsView All Institutional Transactions PTN Stock - Frequently Asked Questions Should I buy or sell Palatin Technologies stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PTN shares. View PTN analyst ratings or view top-rated stocks. What is Palatin Technologies' stock price forecast for 2023? 2 brokerages have issued 1-year price objectives for Palatin Technologies' shares. Their PTN share price forecasts range from $50.00 to $70.00. On average, they anticipate the company's share price to reach $60.00 in the next twelve months. This suggests a possible upside of 2,566.7% from the stock's current price. View analysts price targets for PTN or view top-rated stocks among Wall Street analysts. How have PTN shares performed in 2023? Palatin Technologies' stock was trading at $3.87 at the beginning of the year. Since then, PTN stock has decreased by 41.9% and is now trading at $2.25. View the best growth stocks for 2023 here. How were Palatin Technologies' earnings last quarter? Palatin Technologies, Inc. (NYSEAMERICAN:PTN) issued its quarterly earnings data on Tuesday, May, 16th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.39) by $0.24. The biopharmaceutical company had revenue of $1.20 million for the quarter, compared to the consensus estimate of $1.09 million. Palatin Technologies had a negative net margin of 766.11% and a negative trailing twelve-month return on equity of 278.73%. During the same quarter last year, the firm posted ($0.75) earnings per share. When did Palatin Technologies' stock split? Shares of Palatin Technologies reverse split on Wednesday, August 31st 2022. The 1-25 reverse split was announced on Wednesday, August 31st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 31st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Palatin Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Alliqua Biomedical (ALQA), Catalyst Pharmaceuticals (CPRX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), TherapeuticsMD (TXMD) and Actinium Pharmaceuticals (ATNM). What is Palatin Technologies' stock symbol? Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN." Who are Palatin Technologies' major shareholders? Palatin Technologies' stock is owned by a variety of retail and institutional investors. Top institutional investors include Jane Street Group LLC (0.34%), Montis Financial LLC (0.19%), Susquehanna International Group LLP (0.17%), CIBC Asset Management Inc (0.13%) and Dimensional Fund Advisors LP (0.11%). Insiders that own company stock include Alan W Dunton and Robert K Deveer Jr. View institutional ownership trends. How do I buy shares of Palatin Technologies? Shares of PTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Palatin Technologies' stock price today? One share of PTN stock can currently be purchased for approximately $2.25. How much money does Palatin Technologies make? Palatin Technologies (NYSEAMERICAN:PTN) has a market capitalization of $25.09 million and generates $1.47 million in revenue each year. The biopharmaceutical company earns $-36,200,000.00 in net income (profit) each year or ($2.96) on an earnings per share basis. How can I contact Palatin Technologies? Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The official website for the company is www.palatin.com. The biopharmaceutical company can be reached via phone at (609) 495-2200, via email at investors@palatin.com, or via fax at 609-495-2202. This page (NYSEAMERICAN:PTN) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palatin Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.